Versant Capital Management
FDMT icon

Versant Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Versant Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.4K Hold
728
– – ﹤0.01% 2252
2026
Q2 		$9.7K Buy
728
+113
+18% +$1.1K ﹤0.01% 2241
2026
Q1 		$5.73K Hold
615
– – ﹤0.01% 2342
2025
Q4 		$4.61K Hold
615
– – ﹤0.01% 2282
2025
Q3 		$5.34K Buy
+615
New +$3.68K ﹤0.01% 2180

Other funds holding FDMT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Perigon Wealth Management
Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Versant Capital Management's FDMT Position: Q3 2026 in Review

Versant Capital Management held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 728 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

Versant Capital Management first reported a position in FDMT in Q3 2025 and has held it in 5 quarters since. 54 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Versant Capital Management held 728 shares of 4D Molecular Therapeutics worth $10.4K as of Q3 2026.
  • Versant Capital Management left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2252 holding.
  • Versant Capital Management first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 54 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.